d -Dimer Testing to Determine the Duration of Anticoagulation Therapy
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The optimal duration of oral anticoagulation in patients with idiopathic venous thromboembolism is uncertain. Testing of D-dimer levels may play a role in the assessment of the need for prolonged anticoagulation. METHODS: We performed D-dimer testing 1 month after the discontinuation of anticoagulation in patients with a first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received a vitamin K antagonist for at least 3 months. Patients with a normal D-dimer level did not resume anticoagulation, whereas those with an abnormal D-dimer level were randomly assigned either to resume or to discontinue treatment. The study outcome was the composite of recurrent venous thromboembolism and major bleeding during an average follow-up of 1.4 years. RESULTS: The D-dimer assay was abnormal in 223 of 608 patients (36.7%). A total of 18 events occurred among the 120 patients who stopped anticoagulation (15.0%), as compared with 3 events among the 103 patients who resumed anticoagulation (2.9%), for an adjusted hazard ratio of 4.26 (95% confidence interval [CI], 1.23 to 14.6; P=0.02). Thromboembolism recurred in 24 of 385 patients with a normal D-dimer level (6.2%). Among patients who stopped anticoagulation, the adjusted hazard ratio for recurrent thromboembolism among those with an abnormal D-dimer level, as compared with those with a normal D-dimer level, was 2.27 (95% CI, 1.15 to 4.46; P=0.02). CONCLUSIONS: Patients with an abnormal D-dimer level 1 month after the discontinuation of anticoagulation have a significant incidence of recurrent venous thromboembolism, which is reduced by the resumption of anticoagulation. The optimal course of anticoagulation in patients with a normal D-dimer level has not been clearly established. (ClinicalTrials.gov number, NCT00264277 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,783
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079
Heit, J. A., Mohr, D. N., Silverstein, M. D., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.761 · Cited by 1,352
Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D'Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01109-9 · Cited by 1,333
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Schulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis
Agnelli, G., Prandoni, P., Santamaria, M. G., Bagatella, P., Iorio, A., Bazzan, M., Moia, M., Guazzaloca, G., Bertoldi, A., Tomasi, C., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450302 · Cited by 591
Self-citationO'Neill, D. D., Westerman, D. P., & Sacco, W. (1966) · doi:10.21236/ad0635168 · Cited by 566
Pinede, L., Ninet, J., Duhaut, P., Chabaud, S., Demolombe-Rague, S., Durieu, I., Nony, P., Sanson, C., & Boissel, J.-P. (2001) · Circulation · doi:10.1161/01.cir.103.20.2453 · Cited by 408
Research works printed but not linked: 1
- Kearon C, 2003, CMAJ, 168, 183
Cited by
Items 301–400 of 619
Management of idiopathic venous thromboembolism
Cosmi, B. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1248406 · Cited by 12
Self-citationHolley, A. B., King, C. S., Jackson, J. L., & Moores, L. K. (2010) · Thrombosis · doi:10.1155/2010/540386 · Cited by 10
“Two studies were combined because one [18] reported extended follow-up data on the same patient group enrolled in the other [19].”
BackgroundResultInfluentialVrotniakaite-Bajerciene, K., Rütsche, S., Calzavarini, S., Quarroz, C., Stalder, O., Méan, M., Righini, M., Staub, D., Beer, J. H., Frauchiger, B., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186050 · Cited by 12
An Intact Dissecting Baker’s Cyst Mimicking Recurrent Deep Vein Thrombosis
Jamshed, S., & Snyder, L. M. (2016) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709616650703 · Cited by 10
Imberti, D., Pomero, F., & Mastroiacovo, D. (2020) · Blood transfusion · doi:10.2450/2019.0265-18 · Cited by 12
Management of Venous Thromboembolism
Burnett, B. (2012) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2012.11.004 · Cited by 10
Sullivan, L. T., Jackson, L. R., & Thomas, K. L. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1352-5 · Cited by 10
Biomarkers of Cancer-Associated Thromboembolism
Mahajan, A., & Wun, T. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-20315-3_5 · Cited by 10
VTE recurrence in patients with inherited deficiencies of natural anticoagulants
Gianni, M., & Dentali, F. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-11-0763 · Cited by 10
“showed that patients one month after discontinuation of anticoagulation with an abnormal D-dimer level had a significantly higher incidence of recurrent VTE compared to patients with normal D-dimer, and that resumption of anticoagulation was effective in reducing thromboembolic complications in these patients (7).”
BackgroundThe Future of Deep Venous Thrombosis and Post-thrombotic Syndrome in 2020
Comerota, A. J. (2012) · Phlebology The Journal of Venous Disease · doi:10.1258/phleb.2011.012s08 · Cited by 10
Upper extremity deep vein thrombosis – not the same disease at a different site
Watson, H. G. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03061.x · Cited by 10
Marcucci, M., Smith, C. T., Douketis, J. D., Tosetto, A., Baglin, T. P., Cushman, M., Eichinger, S., Palareti, G., Poli, D., Tait, R. C., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.08.007 · Cited by 11
Self-citationStopping anticoagulant therapy after an unprovoked venous thromboembolism
Kearon, C. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.081080 · Cited by 10
Venous thromboembolism in women
Rathbun, S. W. (2008) · Vascular Medicine · doi:10.1177/1358863x07085404 · Cited by 11
Anticoagulation and compression therapy for proximal acute deep vein thrombosis
Palareti, G., Santagata, D., Ponti, C. D., Ageno, W., & Prandoni, P. (2024) · VASA · doi:10.1024/0301-1526/a001138 · Cited by 9
Self-citationThe dos, don'ts, and nuances of thrombophilia testing
Chiasakul, T., & Bauer, K. A. (2023) · Hematology · doi:10.1182/hematology.2023000491 · Cited by 9
Legnani, C., Pengo, V., Ghirarduzzi, A., Testa, S., Poli, D., Prisco, D., Tripodi, A., Palareti, G., Cosmi, B., & for the PROLONG Investigators FCSA, I. F. O. A. C. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-01-0041 · Cited by 9
“The aim of this study was to assess whether common thrombophilic defects, such as FVL and FII mutation, are associated with RVO presence after a standard course of anticoagulation for a first episode of idiopathic proximal DVT of the lower limbs, with or without symptomatic PE, in consecutive subjects enrolled in two…”
BackgroundMethodInfluentialSelf-citationBewertung des Rezidivthrombose-risikos venöser Thromboembolien
Lindhoff‐Last, E. (2010) · Hämostaseologie · doi:10.5482/ha-1144 · Cited by 9
“Alle Patienten mit einem negativen D-Dimertest nach Absetzen der Antikoagulation erhielten keine erneute Antikoagulation, während die Patienten mit positivem D-Dimer-Ergebnis randomisiert wurden und entweder eine erneute orale Antikoagulation erhielten oder Placebo (13).”
BackgroundDiagnosis and management of venous thromboembolism: an update a decade into the new millennium.
Emadi, A., & Streiff, M. B. (2011) · PubMed · Cited by 12
Turrini, M., & Bourgain, C. (2020) · Social Science & Medicine · doi:10.1016/j.socscimed.2020.112903 · Cited by 12
Optimal duration of anticoagulation in patients with venous thromboembolism.
Prandoni, P., Piovella, C., Spiezia, L., Valle, F. D., & Pesavento, R. (2011) · PubMed Central · Cited by 13
Bauer, K. A. (2011) · JAMA · doi:10.1001/jama.2011.361 · Cited by 11
Management of deep vein thrombosis to reduce the incidence of post-thrombotic syndrome
Lowe, G. D. O. (2010) · Phlebology The Journal of Venous Disease · doi:10.1258/phleb.2010.010s02 · Cited by 10
Critical Care Management of Bariatric Surgery Complications
Chand, B., & Prathanvanich, P. (2015) · Journal of Intensive Care Medicine · doi:10.1177/0885066615593067 · Cited by 8
“New evidence has shown that following D-dimer levels in patients with PE may help predict the duration of anticoagulation therapy.(83)”
BackgroundThe Diagnosis and Management of Early Deep Vein Thrombosis
Hansrani, V., Khanbhai, M., & McCollum, C. N. (2016) · Advances in experimental medicine and biology · doi:10.1007/13780_2016_22 · Cited by 8
First Episode and Recurrent Venous Thromboembolism: Who is Identifiably at Risk?
Liem, T. K., & DeLoughery, T. G. (2008) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2008.05.006 · Cited by 9
Kearon, C. (2010) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2010.06.003 · Cited by 9
Long-term prognosis and related factors towards patients with acute pulmonary thromboembolism.
Gong, X., Duan, Z., & Yuan, Y. (2015) · Europe PMC (PubMed Central) · Cited by 8
Beyer‐Westendorf, J., Gehrisch, S., Stange, T., Tittl, L., Siegert, G., & Weiss, N. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.06.003 · Cited by 8
Wang, Y., Liu, Z.-H., Zhang, H., Luo, Q., Zhao, Z., & Zhao, Q. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0625-2 · Cited by 8
Ageno, W., Cosmi, B., Ghirarduzzi, A., Santoro, R., Bucherini, E., Poli, D., Prisco, D., Alatri, A., Pengo, V., Galli, L., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23198 · Cited by 8
Self-citationUpdate in the Treatment of Venous Thromboembolism
Garcia, D. A., & Spyropoulos, A. C. (2008) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2008-1047561 · Cited by 8
“An elevated plasma D-dimer level, measured 30 days after warfarin has been discontinued, is associated with an increased risk for VTE recurrence.(52) The ‘‘quality’’ of anticoagulation a patient receives is also important.”
Djulbegovic, M., Lee, A. I., & Chen, K. M. (2019) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13194 · Cited by 9
Evaluation the value of markers for prediction of portal vein thrombosis after devascularization
Fei, Y., Zong, G.-Q., & Jian Chen, R.-M. L. (2015) · Annals of Hepatology · doi:10.5604/16652681.1171772 · Cited by 8
Plasma D‐dimer level in the perioperative period in non‐small‐cell lung cancer
Wang, Z., Fu, J., Diao, D., & Dang, C. (2011) · Thoracic Cancer · doi:10.1111/j.1759-7714.2011.00055.x · Cited by 7
Diagnosis and Anticoagulant Treatment
Nicolaides, A. N., Fareed, J., Kakkar, A. K., Comerota, A. J., Goldhaber, S. Z., Hull, R., Myers, K., Samama, M. M., Fletcher, J. M., Kalodiki, E., et al. (2013) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612474840n · Cited by 8
Palareti, G., Legnani, C., Tosetto, A., Poli, D., Testa, S., Ageno, W., Pengo, V., Cosmi, B., & Prandoni, P. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2024.04.018 · Cited by 7
Self-citationOllivier‐Hourmand, I., Lebedel, L., Bartrolí, B., Goria, O., Bureau, C., Dumortier, J., Heurgué, A., Silvain, C., de Lédinghen, V., Rautou, P., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.016 · Cited by 9
Respiratory Review of 2013: Pulmonary Thromboembolism
Hwang, H.-G., & Schulman, S. (2013) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2013.75.3.89 · Cited by 9
Gene microarray analyses for potential biomarkers of single and recurrent venous thromboembolism
Zhou, W., Zhang, K., CHEN, D., Gao, P., & Wang, Q. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4349 · Cited by 11
“However, to date, methods for effectively preventing and diagnosing SVTE and RVTE have remained controversial (22).”
InfluentialUpdate on Pharmacologic Therapy for Pulmonary Embolism
Harikrishnan, P., Palaniswamy, C., & Aronow, W. S. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413506612 · Cited by 9
Varol, A., Köktürk, N., Kılıç, H., Aydoğdu, M., & Ekim, N. (2012) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1011-9 · Cited by 7
Medical Management of Pulmonary Embolism: Beyond Anticoagulation
Hsu, N. Y.-H., Wang, T. S., Friedman, O., & Barjaktarević, I. (2017) · Techniques in vascular and interventional radiology · doi:10.1053/j.tvir.2017.07.004 · Cited by 8
An, J., Sun, B., Ji, Y., Zhang, Z., Zhai, Z., & Wang, C. (2020) · The Clinical Respiratory Journal · doi:10.1111/crj.13167 · Cited by 8
Betensky, M., Mueller, M. G., Amankwah, E. K., & Goldenberg, N. A. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1708879 · Cited by 7
“6 We therefore sought in the present work to: (1) define the incidence of marked rise in coagulability over the first 3 months postdiagnosis of VTE in a multi-institutional population of patients < 21 years old with provoked VTE; (2) investigate its relationship with elevated D-dimer; and (3) test the hypothesis that…”
BackgroundSiragusa, S., Caramazza, D., & Malato, A. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07578.x · Cited by 7
Guided duration of anticoagulation after unprovoked venous thromboembolism using D-dimer testing
Couturaud, F. (2016) · European Respiratory Journal · doi:10.1183/13993003.00212-2016 · Cited by 7
Risk of recurrent ischemic stroke in patients with patent foramen ovale: The role of D-dimer
Park, S.-H., Kwon, B., Oh, J. K., Song, J., Lee, J. S., & Kwon, S. U. (2023) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2023.107246 · Cited by 6
Scoring Systems for Estimating the Risk of Recurrent Venous Thromboembolism
Nichele, I., & Tosetto, A. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1602662 · Cited by 7
Self-citationWang, J., TACEY, M. A., & Ho, P. W. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02101-y · Cited by 7
Anticoagulants: dose control methods and inhibitors
Bitsadze, V. O., Викторовна, С. Е., Khizroeva, J. K., Tretyakova, M. V., Tsibizova, V. I., Gashimova, N. R., Nakaidze, I. A., Elalamy, I., Gris, J., & Makatsariya, A. D. (2022) · Obstetrics Gynecology and Reproduction · doi:10.17749/2313-7347/ob.gyn.rep.2022.293 · Cited by 7
Sista, A. K. (2014) · Techniques in vascular and interventional radiology · doi:10.1053/j.tvir.2014.02.011 · Cited by 6
Matsuda, S., Imazu, T., Kimura, R., Nakamura, M., Matsumoto, A., Murakami, T., & Maeda, Y. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000336 · Cited by 6
Tritschler, T., Limacher, A., Méan, M., Rodondi, N., & Aujesky, D. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.018 · Cited by 7
Coagulation state in patients with Crohn’s disease
Wang, X., Wang, G., Wang, J., Liu, S., Zhou, R., Chen, L., Wu, T., Huang, M., Li, J., Song, L., et al. (2014) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000133 · Cited by 6
Ginsberg, J. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00081-6 · Cited by 6
Pulmonary Embolism and Deep Vein Thrombosis
Currier, P. F., & Hales, C. A. (2010) · Springer eBooks · doi:10.1007/978-0-387-87429-6_86 · Cited by 7
d -Dimer Testing in Patients With a First Unprovoked Venous Thromboembolism
Palareti, G. (2015) · Annals of Internal Medicine · doi:10.7326/l15-5089 · Cited by 6
Self-citationWhat's new in the other general journals
Tonks, A. (2006) · BMJ · doi:10.1136/bmj.332.7536.289 · Cited by 6
Tripodi, A., Legnani, C., & Palareti, G. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13151 · Cited by 6
Self-citationThrombophilia screening or screaming
Keeling, D. M. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03871.x · Cited by 5
Thrombosis and thrombophilia: principles for pediatric patients
Trenor, C. C. (2010) · Blood Coagulation & Fibrinolysis · doi:10.1097/01.mbc.0000388937.62364.f5 · Cited by 5
Li, D., Liu, Y., Song, Y. H., & Wen, A. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2026002 · Cited by 5
“For example, Eischer [31] included VTE patients with high factor VIII (FVIII) (>230 IU/dL); we had only included patients with elevated D-dimer in the PROLONG study [34].”
BackgroundHimeno, M., Nagatomo, Y., Miyauchi, A., Sakamoto, A., Kiyose, K., Iwashita, M., Kawai, A., Naganuma, T., Maekawara, S., Naito, A., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020226 · Cited by 6
“So far, the predictive value of D-dimer during anticoagulant therapy or after its cessation has been explored mostly for VTE recurrence [43,44].”
BackgroundDurée optimale du traitement anticoagulant au décours d’une embolie pulmonaire
Couturaud, F. (2011) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2011.04.017 · Cited by 7
Residual thrombosis after a first episode of proximal deep venous thrombosis
Montes‐Worboys, A., Arellano, E., Elías-Hernández, T., León, J., Rodríguez-Portal, J.-A., & Otero, R. (2013) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32835c32ef · Cited by 5
Duration of Anticoagulation for Venous Thromboembolic Events
Smilowitz, N. R., Mega, J. L., & Berger, J. S. (2014) · Circulation · doi:10.1161/circulationaha.114.010456 · Cited by 6
White, R. H. R., & Murin, S. (2009) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32832d044a · Cited by 5
Maintenance of warfarin therapy at an anticoagulation clinic.
Jacobson, B. F., Schapkaitz, E., Haas, S. K., Dalby, T., Mer, M., Patel, M., Middlemost, S. J., Münster, M., Adler, D., Alli, N., et al. (2007) · PubMed · Cited by 5
Quelle est la durée du traitement anticoagulant pour une EP/TVP proximale ?
Couturaud, F., Girard, P., Laporte, S., & Sanchez, O. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2019.05.022 · Cited by 5
Wang, J., Lim, H. Y., & Ho, P. W. (2021) · Hemato · doi:10.3390/hemato2010003 · Cited by 7
Burggraaf, J. L. I., van Rein, N., Bemelmans, R. H. H., van den Berg, J. W., Bruggeman, C. Y., Balen, M. C., Coppens, M., Eefting, M., Ende-Verhaar, Y. M., van Es, N., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-078676 · Cited by 5
“28 39 One study showed a clear benefit of prolonged anticoagulant Open access treatment compared with discontinuation on recurrent VTE in patients with an unprovoked VTE and elevated d-dimer levels 1 month after ceasing anticoagulant treat-ment (2.9% vs 15% during 9–18 months of follow-up,…”
BackgroundInfluentialPrimary Prevention of Venous Thromboembolism: Current State
Frolov, D. V., Petrov, V. I., Суханова, Г. А., Линченко, Д. В., Nalesnyi, A. E., & Dyachkova, Y. A. (2022) · Journal of Venous Disorders · doi:10.17116/flebo202216021164 · Cited by 5
Davis, R., Bansal, V., Litinas, E., Hoppensteadt, D., Thethi, I., Nelson, K. K., & Fareed, J. (2011) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029610397752 · Cited by 5
Normal D-Dimer Concentration in Hospitalized Patients with Lung Diseases
Fijałkowska, A., Wiatr, E., Kurzyna, M., Kuca, P., Burakowski, J., Kober, J., Szturmowicz, M., Wawrzyńśka, L., Roszkowska-Śliż, B., Tomkowski, W. Z., et al. (2012) · Advances in respiratory medicine · doi:10.5603/arm.27596 · Cited by 5
Distal deep vein thrombosis – a benign disease?
Schulman, S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.04.001 · Cited by 5
Update in General Internal Medicine
Knight, C. L., & Fihn, S. D. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-1-200607040-00010 · Cited by 5
Rinde, F. B., Jørgensen, C. T., Pettersen, H. H., Hansen, J., Ghanima, W., & Brækkan, S. K. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.03.026 · Cited by 5
Tripodi, A., Capecchi, M., Scalambrino, E., Clerici, M., Scimeca, B., Agosti, P., Bucciarelli, P., & Peyvandi, F. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013193 · Cited by 7
Self-citationdel Pozo, M. M., Asenjo, M. M., Franco‐Moreno, A., de Antonio, E. U., & Valle, F. G. (2024) · Revista Clínica Española · doi:10.1016/j.rce.2024.07.007 · Cited by 4
Regulation and Clinical Application of Exosomes in Venous Thrombosis
Shao, F., He, R., Yang, J., Pang, Y., Sun, Z., Zhang, B., & Jin, S. H. (2025) · Angiology · doi:10.1177/00033197251319597 · Cited by 4
“25,54 Wojcik et al. 55 discovered that IL-6 was related to fibrosis and that neutralizing IL-6 through systemic injection of antibodies in a stationary DVT model can accelerate thrombus regression, reduce monocyte recruitment, and reduce venous wall fibrosis.”
Aziz, F., & Comerota, A. J. (2013) · Journal of Radiology Nursing · doi:10.1016/j.jradnu.2013.06.001 · Cited by 4
Imaging and Laboratory Diagnosis
Caplan, L. R. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4721-6.50006-7 · Cited by 5
Initial and Long-Term Treatment of Pulmonary Embolism: Current Approach and Future Perspectives
Ageno, W., & Donadini, M. P. (2018) · Hämostaseologie · doi:10.1055/s-0038-1641605 · Cited by 4
Miller, M. J., Maier, C. L., Duncan, A., & Guarner, J. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211032292 · Cited by 4
“Most hospital laboratories offer measurement of D-dimer as a marker of recent or ongoing fibrinolysis and clinicians may use the results to assess risk of thrombosis.(2) Importantly, D-dimer values above the reference range can be seen in a variety of situations not necessarily related to activation of the coagulation…”
BackgroundThachil, J. V. (2012) · QJM · doi:10.1093/qjmed/hcs023 · Cited by 4
Montes, R., Guruceaga, E., González‐Porras, J. R., Reverter, J. C., Marco, P., Pina, E., Páramo, J. A., Hermida, J., Lecumberri, R., & (SETH), G. D. T. D. P. T. D. L. S. E. D. T. Y. H. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12692 · Cited by 4
“On the other hand, in clinical practice it may be difficult for patients and physicians to resume anticoagulant therapy in case of a positive result (7, 8).”
BackgroundMoneta, G. L. (2010) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2010.05.123 · Cited by 4
Recurrence risk of idiopathic venous thromboembolism
Franco‐Moreno, A., Aracil, C. D. A., & Navarro, M. J. G. (2016) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2016.06.002 · Cited by 5
Guías de práctica clínica sobre diagnóstico y manejo del tromboembolismo pulmonar agudo
(ESC), G. D. T. P. E. D. Y. M. D. T. P. A. D. L. S. E. D. C. (2008) · Revista Española de Cardiología · doi:10.1016/s0300-8932(08)75741-5 · Cited by 6
Pregnancy associated coagulopathies in selected community hospitals in Southwest Nigeria
Bamisaye, O. E., Michael, O. A., Oluwafemi, A. E., & David, A. B. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1381_20 · Cited by 4
“Although detectable during the first trimester, placenta‐derived PAI‐2 also increases substantially throughout pregnancy.[35,36] These changes reflect an impaired fibrinolytic system which if it is consistent and detected early enough can be used to rule in/out pulmonary embolism and deep venous thrombosis using the p…”
Aplicabilidad clínica de la determinación de dímero-D en pacientes con cáncer
Lecumberri, R., Pegenaute, C., & Páramo, J. A. (2010) · Medicina Clínica · doi:10.1016/j.medcli.2010.07.018 · Cited by 4
Facteurs de risque de récidive de la maladie thromboembolique veineuse
Rosencher, J., Mirault, T., Martínez, I. S., Zhu, T., Messas, E., & Emmerich, J. (2011) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2010.10.036 · Cited by 8
The Treatment of Deep Vein Thrombosis in the Pelvis and Leg
Hach-Wunderle, V., Düx, M., Hoffmann, A., Präve, F., Zegelman, M., & Hach, W. (2008) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2008.0025 · Cited by 15
Palareti, G. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2015.975791 · Cited by 4
“In the PROLONG [51] and PROLONG II [56] collaborative studies, D-dimer levels were evaluated using a qualitative assay (Clearview Simplify D-dimer by Inverness Medical Professional Diagnostics, Bedford, UK and Luisville, Colorado, USA), How D-dimer assay can be useful in deciding the duration of anticoagulation after…”
BackgroundMethodInfluentialSelf-citationSmitherman, A. B., & Weston, B. W. (2014) · Journal of Infusion Nursing · doi:10.1097/nan.0000000000000025 · Cited by 6
Toshima, H., Hisamatsu, A., Kobayashi, K., Ishida, H., & Shimada, K. (2020) · Cancers · doi:10.3390/cancers12071711 · Cited by 4
d -Dimer Testing in Patients With a First Unprovoked Venous Thromboembolism
Kearon, C., Stevens, S. M., & Julian, J. A. (2015) · Annals of Internal Medicine · doi:10.7326/l15-5089-2 · Cited by 4
Duration of anticoagulant therapy for patients with venous thromboembolism
Garcia, D. A. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.08.019 · Cited by 4
“[7] Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, et al.”
BackgroundDurée optimale du traitement anticoagulant au décours d’une maladie veineuse thrombo-embolique
Savina, E. N., & Couturaud, F. (2011) · Journal des Maladies Vasculaires · doi:10.1016/s0398-0499(11)70005-1 · Cited by 3
Metadata
- Authors
- Palareti, G., Cosmi, B., Legnani, C., Tosetto, A., Brusi, C., Iorio, A., Pengo, V., Ghirarduzzi, A., Pattacini, C., Testa, S., Lensing, A. W. A., & Tripodi, A.
- Affiliations
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Ospedale San Bortolo (IT)
- University of Perugia (IT)
- Azienda Ospedale - Università Padova (IT)
- Santa Maria Nuova Hospital (IT)
- Istituti Ospitalieri di Cremona (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-26
- Volume
- 355
- Issue
- 17
- Pages
- 1780-1789
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2047986798
- Cited by
- 622
- References
- 25
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 12 · 2023: 11 · 2022: 14 · 2021: 16 · 2020: 34 · 2019: 22 · 2018: 20 · 2017: 19 · 2016: 40 · 2015: 41 · 2014: 40 · 2013: 38 · 2012: 53
- FWCI
- 35.51
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
- Keywords
- D-dimer, anticoagulation duration, venous thromboembolism, deep vein thrombosis, pulmonary embolism, vitamin K antagonists, recurrence, major bleeding, unprovoked thrombosis, anticoagulation resumption
- MeSH terms
- Acenocoumarol, Adult, Aged, Aged, 80 and over, Anticoagulants, Antithrombins, Drug Administration Schedule, Fibrin Fibrinogen Degradation Products, Follow-Up Studies, Hemorrhage, Humans, Middle Aged, Prospective Studies, Pulmonary Embolism, Recurrence, Ultrasonography, Vitamin K, Warfarin, Proportional Hazards Models, Survival Analysis, Antiphospholipid Syndrome, Venous Thrombosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.